GlySure Completes Enrollment in Cardiac ICU CE Mark Trial
GlySure October 2013
GlySure making important progress in delivering continuous blood glucose monitoring (CBGM) technology to the healthcare marketplace
GlySure Limited today announced that it has completed patient enrollment for the multicenter CE Mark trial of its in-hospital continuous blood glucose monitoring (CBGM) system. The trial, led by Principal Investigator Dr. Krishna Prasad, comprised 30 post surgery cardiac intensive care unit patients.
Over the past two years, Dr. Prasad has tested the GlySure CBGM system in over 160 intensive care unit (ICU) patients demonstrating high levels of accuracy and repeatability for up to five days of continuous monitoring. He comments on this next stage of the technology’s development.
“For over a decade, the clinical community has been seeking a way to tightly control glucose levels in ICU patients that enables them to perform this function with accuracy, reliability and efficiency,” said Dr. Prasad. “Our trials to date indicate that GlySure’s technology can address the decade-long demand for better ICU glycemic control and I am excited to embark on this next stage of its testing.”
“We’ve made tremendous progress in 2013 with the advancements in our technology, expansion of intellectual property and completion of enrollment in our CE Mark trial,” said GlySure CEO Chris Jones. “The CE Mark trial is another significant milestone in our company’s development. We look forward to being able to bring this product to market and engaging with European clinicians to deliver simple, accurate and effective glycemic control for ICU patients.”